At this year’s Hill Day, attendees will receive in-depth training on Medicare reimbursement and hear from Rep. Larry Bucshon, MD, (R-Ind.) about his perspective on the issue as a physician in Congress.
Advocacy Leadership Conference to Support Inflation-Linked Medicare Payment Increases
On May 7, ACR leaders from the Board of Directors, committees and more will to go to Capitol Hill and ask lawmakers to support legislation that would stabilize Medicare reimbursement for physicians.
CMS Updates the Medicare Conversion Factor
The Consolidated Appropriations Act, 2024 increased the Medicare conversion factor by 1.68% effective March 9, bringing it to $33.2875 for March 9–Dec. 31, 2024.
UnitedHealthcare Updates Reimbursement for Infliximab Biosimilars
On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
ACR Voices Support for the Healthcare Workforce Resilience Act
The ACR joined with 52 organizations in thanking House and Senate leaders for introducing the Healthcare Workforce Resilience Act, which would support employment-based visas for international physicians and nurses.
Spring 2024 State Legislative Update
The ACR is actively monitoring more than 60 pieces of legislation, focusing on such key issues as copay accumulators, utilization management reform, gold card programs and other emerging concerns. Two states have passed utilization management reform bills this year.
Congressional Action Partially Addresses Medicare Cuts
The newest funding package reduces the latest cut to Medicare reimbursement from 3.4% to 1.68%. Although rheumatologists are faring better under Medicare in 2024, broader reforms remain the ACR’s highest priority regarding Medicare payments to physicians.
RheumPAC’s Role in the ACR’s Advocacy Efforts
In an election year, it is critical that the ACR’s non-partisan political action committee be well positioned to support our congressional champions. Learn more about RheumPAC and its role in the ACR’s advocacy efforts.
2024 State Legislative Preview
With state legislatures now in session, the ACR is working with our partners to ensure that the voice of the rheumatology community is heard. Here is a look at some of the bills we are monitoring and the trends we expect to play out over the 2024 legislative calendar.
The Biosimilar Economic Conundrum: Where We Stand
Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
- 1
- 2
- 3
- …
- 83
- Next Page »